appalling price action - smells to me like there is a profit downgrade coming it's uncanny how few mid cap co's in Australia are unable to support their high debt loads, this looks like just another one of them
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%